Supplementary Figures 1-12, Supplementary Tables 1-2 from The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in Colorectal Cancer

Abstract

<p>Supplementary Figure 1. BET inhibition reduces MYC expression and MYC-dependent transcription; Supplementary Figure 2. BET inhibition impairs proliferation and survival of CRC cells; Supplementary Figure 3. Phosphorylation status of ERK in CRC cell lines; Supplementary Figure 4. BET inhibition sensitizes CRC cells to inhibitors of the MAPK pathway; Supplementary Figure 5. The combination of JQ1 and trametinib impairs colony formation in CRC cells; Supplementary Figure 6. Depletion of BRD4 sensitizes CRC cells to trametinib; Supplementary Figure 7. Knockdown of KRAS recapitulates the ability of MAPK pathway inhibitors to sensitize CRC cells to JQ1; Supplementary Figure 8. Response to JQ1 {plus minus} trametinib in DLD1 and derivative lines; Supplementary Figure 9. Response to JQ1 {plus minus} trametinib in RKO and derivative lines; Supplementary Figure 10. (A) MYC mRNA levels in RKO cells treated with 500 nmol/L JQ1 {plus minus} 50 nmol/L trametinib for 2 days; Supplementary Figure 11. Co-targeting of BET proteins and MEK effectively shifts expression of apoptotic regulators to promote apoptosis; Supplementary Figure 12. The combination of JQ1 and trametinib induced CRC xenograft tumor Regression; Supplementary Table 1. Real-time PCR primers used in this study; Supplementary Table 2. Genotypes and IC50 values for JQ1 and trametinib in CRC cell lines.</p>